Charles River Laboratories (CRL) : Globeflex Capital L P scooped up 260 additional shares in Charles River Laboratories during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 10, 2016. The investment management firm now holds a total of 41,567 shares of Charles River Laboratories which is valued at $3,446,736.Charles River Laboratories makes up approximately 0.89% of Globeflex Capital L P’s portfolio.
Other Hedge Funds, Including , Blackrock Group Ltd reduced its stake in CRL by selling 2,304 shares or 3.9% in the most recent quarter. The Hedge Fund company now holds 56,734 shares of CRL which is valued at $4,704,383.Olstein Capital Management boosted its stake in CRL in the latest quarter, The investment management firm added 31,615 additional shares and now holds a total of 55,901 shares of Charles River Laboratories which is valued at $4,714,131. Charles River Laboratories makes up approx 0.60% of Olstein Capital Management’s portfolio. Quantbot Technologies Lp added CRL to its portfolio by purchasing 361 company shares during the most recent quarter which is valued at $31,032.Wright Investors Service Inc boosted its stake in CRL in the latest quarter, The investment management firm added 670 additional shares and now holds a total of 9,155 shares of Charles River Laboratories which is valued at $786,964. Charles River Laboratories makes up approx 0.31% of Wright Investors Service Inc’s portfolio. Highland Capital Management added CRL to its portfolio by purchasing 11,568 company shares during the most recent quarter which is valued at $996,930. Charles River Laboratories makes up approx 0.08% of Highland Capital Management’s portfolio.
Charles River Laboratories closed down -0.7 points or -0.84% at $82.66 with 1,99,704 shares getting traded on Friday. Post opening the session at $83.24, the shares hit an intraday low of $82.38 and an intraday high of $83.39 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
On the company’s financial health, Charles River Laboratories reported $1.20 EPS for the quarter, beating the analyst consensus estimate by $ 0.10 according to the earnings call on Aug 3, 2016. Analyst had a consensus of $1.10. The company had revenue of $434.10 million for the quarter, compared to analysts expectations of $424.98 million. The company’s revenue was up 27.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.96 EPS.
Many Wall Street Analysts have commented on Charles River Laboratories. Credit Suisse Initiated Charles River Laboratories on Jun 21, 2016 to “Neutral”, Price Target of the shares are set at $84.Company shares were Reiterated by Barclays on May 20, 2016 to “Underweight”, Firm has raised the Price Target to $ 65 from a previous price target of $60 .
Charles River Laboratories International Inc. is a full service early stage contract research company. The Company offers research models for the research and development of new drugs devices and therapies. It develops a portfolio of discovery and safety assessment services both Good Laboratory Practice (GLP) and non-GLP that support the clients from target identification through preclinical development. The Company operates through three segments: Research Models and Services (RMS) which supplies research models to the drug development industry; Discovery and Safety Assessment (DSA) which provides services that enables the clients to outsource their drug discovery research critical regulatory-required safety assessment testing and related drug discovery and development activities and Manufacturing Support (Manufacturing) which is involved in the production and release of products manufactured by the clients.